Suppr超能文献

青少年系统性红斑狼疮患者霉酚酸的药代动力学及两种药物暴露有限采样策略的外部评估

Pharmacokinetics of mycophenolic acid and external evaluation of two limited sampling strategies of drug exposure in patients with juvenile systematic lupus erythematosus.

作者信息

Beaulieu Quentin, Zhang Daolun, Melki Isabelle, Baudouin Véronique, Goldwirst Lauriane, Woillard Jean-Baptiste, Jacqz-Aigrain Evelyne

机构信息

Paediatric Pharmacology, Department of Biological Pharmacology, Saint-Louis University Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France.

General Pediatrics, Infectious Disease and Internal Medicine Department, Robert Debre University Hospital, Reference Center for Rheumatic, AutoImmune and Systemic Diseases in Children (RAISE), AP-HP, Paris, France.

出版信息

Eur J Clin Pharmacol. 2022 Jun;78(6):1003-1010. doi: 10.1007/s00228-022-03295-1. Epub 2022 Mar 16.

Abstract

INTRODUCTION

Mycophenolate mofetil (MMF), a pro-drug of mycophenolic acid (MPA), has become a major therapeutic option in juvenile systemic lupus erythematosus (jSLE). Monitoring MPA exposure using area under curve (AUC) has proved its value to increase efficacy and safety in solid organ transplantation both in children and adults, but additional data are required in patients with autoimmune diseases. In order to facilitate MMF therapeutic drug monitoring (TDM) in children, Bayesian estimators (BE) of MPA AUC using limited sampling strategies (LSS) have been developed. Our aim was to conduct an external validation of these LSS using rich pharmacokinetics and compare their predictive performance.

METHODS

Pharmacokinetic blood samples were collected from jSLE treated by MMF and MPA plasma concentrations were determined using high-performance liquid chromatography system with ultraviolet detection (HPLC-UV). Individual AUC at steady state was calculated using the trapezoid rule and compared with two LSS: (1) ISBA, a two-stage Bayesian approach developed for jSLE and (2) ADAPT, a non-linear mixed effects model with a parametric maximum likelihood approach developed with data from renal transplanted adults.

RESULTS

We received 41 rich pediatric PK at steady state from jSLE and calculated individual AUC. The external validation MPA AUC was conducted by selecting the concentration-time points adapted to ISBA and ADAPT: (1) ISBA showed good accuracy (bias: - 0.8 mg h/L), (2) ADAPT resulted in a bias of 6.7 mg L/h. The corresponding relative root mean square prediction error (RSME) was 23% and 43% respectively.

CONCLUSION

According to our external validation of two LSS of drug exposure, the ISBA model is recommended for Bayesian estimation of MPA AUC in jSLE. In the literature focusing on MMF TDM, an efficacy cut-off for MPA AUC between 30 and 45 mg h/L is proposed in jSLE but this requires additional validation.

摘要

引言

霉酚酸酯(MMF)是霉酚酸(MPA)的前体药物,已成为青少年系统性红斑狼疮(jSLE)的主要治疗选择。使用曲线下面积(AUC)监测MPA暴露已证明其在儿童和成人实体器官移植中提高疗效和安全性的价值,但自身免疫性疾病患者还需要更多数据。为了便于对儿童进行MMF治疗药物监测(TDM),已开发出使用有限采样策略(LSS)的MPA AUC贝叶斯估计器(BE)。我们的目的是使用丰富的药代动力学对这些LSS进行外部验证,并比较它们的预测性能。

方法

收集接受MMF治疗的jSLE患者的药代动力学血样,并使用带紫外检测的高效液相色谱系统(HPLC-UV)测定MPA血浆浓度。使用梯形法则计算稳态下的个体AUC,并与两种LSS进行比较:(1)ISBA,一种为jSLE开发的两阶段贝叶斯方法;(2)ADAPT,一种使用肾移植成人数据开发的具有参数最大似然法的非线性混合效应模型。

结果

我们从jSLE患者中获得了41个稳态下丰富的儿科药代动力学数据,并计算了个体AUC。通过选择适用于ISBA和ADAPT的浓度时间点进行MPA AUC的外部验证:(1)ISBA显示出良好的准确性(偏差:-0.8mg·h/L),(2)ADAPT的偏差为6.7mg·L/h。相应的相对均方根预测误差(RSME)分别为23%和43%。

结论

根据我们对两种药物暴露LSS的外部验证,建议使用ISBA模型对jSLE患者的MPA AUC进行贝叶斯估计。在关注MMF TDM的文献中,jSLE患者中建议MPA AUC的疗效截止值在30至45mg·h/L之间,但这需要进一步验证。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验